{"id":"NCT00367432","sponsor":"UCB Japan Co. Ltd.","briefTitle":"A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures","officialTitle":"A Multicenter, Open, Long-term Follow-up Study to Evaluate the Safety and Efficacy of L059 (Levetiracetam) at Individual Optimal Dose Ranging From 500 to 3000 mg/Day in Twice Daily Administration in Subjects From 16 to 65 Years With Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized Who Completed in a Previous Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-07","primaryCompletion":"2010-12","completion":"2010-12","firstPosted":"2006-08-22","resultsPosted":"2012-01-16","lastUpdate":"2020-11-13"},"enrollment":398,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsies","Partial"],"interventions":[{"type":"DRUG","name":"Levetiracetam","otherNames":["Keppra"]}],"arms":[{"label":"Levetiracetam","type":"EXPERIMENTAL"}],"summary":"This study is planned to evaluate the safety and efficacy of L059 (levetiracetam) in long-term administration in patients who completed N01020 \\[NCT00160165\\] or N01221 \\[NCT00280696\\].","primaryOutcome":{"measure":"Occurrence of Treatment-emergent Adverse Events During the Study Period (Until the Time of Approval Granted)","timeFrame":"During the study period from Visit 1 (Week 0) to the Follow-up Visit (up to Month 60) until the time of approval granted","effectByArm":[{"arm":"Levetiracetam","deltaMin":381,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":53,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":64,"n":398},"commonTop":["Nasopharyngitis","Somnolence","Contusion","Headache","Diarrhoea"]}}